SAN DIEGO, Dec. 15 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc.
(Nasdaq: ARNA) today announced that it has successfully completed preclinical
studies on its internally discovered compound for obesity, APD356, and remains
on schedule to initiate Phase I human clinical trials in the first quarter of
2004. Arena also announced that...
SAN DIEGO, Oct. 31 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc.
(Nasdaq: ARNA) today announced that Derek T. Chalmers, Ph.D., Vice President,
Research and Director of Arena Pharmaceuticals, Inc., will present at the CIBC
World Markets 14th Annual Healthcare Conference at the Plaza Hotel in New York
City on Tuesday, November 11, ...
SAN DIEGO, Oct 22, 2003 /PRNewswire-FirstCall via COMTEX/ -- Arena Pharmaceuticals, Inc.
(Nasdaq: ARNA) today reported revenues of $2.9 million for the quarter ended
September 30, 2003, compared to third quarter 2002 revenues of $3.0 million,
and $11.2 million in revenues for the nine months ended September 30, 2003,
compared to $13.1 millio...
SAN DIEGO, Oct 20, 2003 /PRNewswire-FirstCall via COMTEX/ -- Arena Pharmaceuticals, Inc.
(Nasdaq: ARNA) today announced that Biotechnology Value Fund, L.P. and certain
of its affiliates accepted Arena's offer to purchase three million shares of
Arena common stock from them at a cash price per share of $7.69. Arena made
the offer on October ...
SAN DIEGO--(BUSINESS WIRE)--Oct. 9, 2003--Arena Pharmaceuticals,
Inc. (NASDAQ:ARNA) announced today that it will release its third
quarter financial results for the period ended September 30, 2003,
after the NASDAQ National Market closes on Wednesday, October 22,
2003, and will host both a telephone and Internet third quarter
conference...
SAN DIEGO, Oct 8, 2003 /PRNewswire-FirstCall via COMTEX/ -- Arena Pharmaceuticals, Inc.
(Nasdaq: ARNA) today announced that the Stockholders Agreement dated as of
January 17, 2003, with its largest stockholder, Biotechnology Value Fund, L.P.
and certain related entities ("BVF"), has been amended, and that the parties
are in discussions about...
SAN DIEGO, Sept. 5 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc.
(Nasdaq: ARNA) today announced that Jack Lief, President and Chief Executive
Officer of Arena Pharmaceuticals, Inc., will present at the UBS Global Life
Sciences Conference at the Plaza Hotel in New York City on Wednesday,
September 24, 2003, at 11:00 a.m. EDT (8:00...
SAN DIEGO, Aug 12, 2003 /PRNewswire-FirstCall via COMTEX/ -- Arena Pharmaceuticals, Inc.
(Nasdaq: ARNA) today reported revenues of $3.0 million for the quarter ended
June 30, 2003, compared to second quarter 2002 revenues of $5.8 million, and
$8.3 million in revenues for the six months ended June 30, 2003, compared to
$10.1 million in revenu...
SAN DIEGO--(BUSINESS WIRE)--July 17, 2003--Arena Pharmaceuticals,
Inc. (NASDAQ:ARNA) announced today that it will release its second
quarter financial results for the period ended June 30, 2003, after
the NASDAQ National Market closes on Tuesday, August 12, 2003, and
will host both a telephone and Internet second quarter conference call
...
SAN DIEGO, May 30 /PRNewswire-FirstCall/ --
Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that Derek T.
Chalmers, Ph.D., Vice President, Research and Director of Arena
Pharmaceuticals, Inc., will present at the Needham & Company Second Annual
Biotechnology Conference at the New York Palace Hotel on Friday, June 6, 2003,
at...
SAN DIEGO, April 30 /PRNewswire-FirstCall/ --
Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that the U.S.
Patent and Trademark Office issued Arena a patent entitled "Non-Endogenous,
Constitutively Activated Human Protein Coupled Receptors." This patent, U.S.
Patent Serial No. 6,555,339, covers one of Arena's proprietary method...
SAN DIEGO, Apr 23, 2003 /PRNewswire-FirstCall via COMTEX/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today reported revenues of
$5.4 million for the quarter ended March 31, 2003, a 27% increase over
revenues of $4.2 million for the quarter ended March 31, 2002. Revenues in
the first quarter of 2003 and 2002 were attributable to research f...
SAN DIEGO, Apr 11, 2003 (BUSINESS WIRE) -- Arena Pharmaceuticals,
Inc. (NASDAQ: ARNA) announced today that it will release its first
quarter financial results for the period ended March 31, 2003, after
the NASDAQ National Market closes on Wednesday, April 23, 2003, and
will host both a telephone and Internet first quarter conference call
on...
SAN DIEGO, Jan. 20 /PRNewswire-FirstCall/ --
Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today reported record revenues of
$6.4 million for the quarter ended December 31, 2002, a 9% increase over
revenues of $5.9 million for the quarter ended December 31, 2001, and record
revenues of $19.4 million for the full year ended December 31, 20...
SAN DIEGO, Jan. 8 /PRNewswire-FirstCall/ --
Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that it has
rescheduled its previously announced fourth quarter earnings call due to the
Martin Luther King holiday on which the markets will be closed. They will
host both a telephone and live internet fourth quarter conference call...
SAN DIEGO--(BUSINESS WIRE)--Jan. 7, 2003--Arena Pharmaceuticals,
Inc. (NASDAQ:ARNA) announced today that it will host both a telephone
and internet fourth quarter conference call on Monday, January 20,
2003 at 4:30 p.m. Eastern Time (1:30 p.m. San Diego Time). The Company
will release financial results for the fourth quarter that after...
SAN DIEGO, Nov. 13 /PRNewswire-FirstCall/ --
Arena Pharmaceuticals, Inc. ("Arena") (Nasdaq: ARNA) announced today that the
three-year research collaboration between Arena and Eli Lilly and Company
("Lilly") will not continue after April 14, 2003. The principle objective of
the research collaboration is the activation and enablement of...
SAN DIEGO, Oct 31, 2002 /PRNewswire-FirstCall via COMTEX/ -- Arena
Pharmaceuticals, Inc. ("Arena") (Nasdaq: ARNA) announced that on October 30,
2002, its Board of Directors approved the adoption of a Stockholders Rights Plan
under which all stockholders of record as of November 13, 2002, will receive
rights to purchase shares of a new series of...
SAN DIEGO, Oct 29, 2002 /PRNewswire-FirstCall via COMTEX/ -- Arena
Pharmaceuticals, Inc. (Nasdaq: ARNA) today reported revenues of $3.0 million for
the quarter ended September 30, 2002, a 14% decrease over revenues of $3.5
million for the quarter ended September 30, 2001, and revenues of $13.1 million
for the nine months ended September 30, 200...
SAN DIEGO, Oct 28, 2002 /PRNewswire-FirstCall via COMTEX/ -- Arena
Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today the appointments of Dr. J.
Clayburn La Force, Jr., and Dr. Duke K. Bristow to the company's Board of
Directors. The new directors have been appointed to fill the vacancies created
by the resignations of Dr. John P. McAlister I...
